뼈 및 미네랄 진단 검사 시장 보고서 : 제품별, 검사 유형별, 용도별, 지역별(2025-2033년)

The global bone and mineral diagnostic testing market size reached USD 1.1 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 1.5 Billion by 2033, exhibiting a growth rate (CAGR) of 3.48% during 2025-2033. A considerable increase in the incidences of bone-related diseases, the escalating demand for early disease diagnosis and prevention, and continual technological advancements in the automation of assay represent some of the key factors driving the market.

Bone and mineral diagnostic tests detect bone and mineral disorders that are performed using technologies, such as ELISA, CLIA, and RIA, to diagnose and assess treatment response. A bone and mineral metabolism disorder is a general term used to describe a range of conditions that can weaken bones due to mineral deficiencies like calcium, phosphorus, and vitamin D. In most cases, these tests are non-invasive, painless, and require minimal medication or administration, and several bone and mineral diagnostic tests are often performed using a combination method. The use of X-rays, computed tomography (CT) scans, or magnetic resonance imaging (MRI) can help identify or rule out fractures, wear and tear, and abnormal bone positions. Additionally, bone density tests (also known as bone densitometry or osteodensitometry) and bone scans (bone scintigraphy) detect the minerals in the bones, details on bone metabolism, and depict the different bone structures. Besides this, bone biopsies and bone marrow biopsies are also important forms of bone diagnostic testing, in which a thin needle is used to remove bone tissue to detect disease-related changes.

Bone and Mineral Diagnostic Testing Market Trends:

A considerable increase in the incidences of bone-related diseases on the global level is a significant factor driving the market. This can be attributed to the rising prevalence of sedentary lifestyle leading to deficiency of vitamin D. In line with this, the escalating demand for early disease diagnosis and prevention is also resulting in a higher uptake of various tests among the masses. Moreover, continual technological advancements in the automation of assay for enhanced diagnostic testing with lower turnaround times and increased accuracy in output are creating lucrative growth opportunities in the market. However, the augmenting costs of several bone diagnostic tests, limited reimbursements, along with limited detection capability are acting as significant factors that are restraining the market growth. On the contrary, the expansion of a wide range of point-of-care (POC) diagnostic tests and a considerable rise in public awareness toward preventive healthcare is creating a positive outlook for the market. The market is further driven by favorable initiatives undertaken by the government and non-profit organizations for promoting awareness about various diagnostic test procedures among the masses. Apart from this, the growing geriatric population that is more susceptible to developing these ailments is leading to the increasing incidences of bone disorders. Some of the other factors contributing to the market include rapid urbanization, rising medical expenditure, new product launches by the manufacturers, and extensive research and development (R&D) activities.

Key Market Segmentation:

Product Insights

Assays/Consumables

Instruments

Test Type Insights

Enzyme-Linked Immunosorbent Assay (ELISA)

Clinical Laboratory Improvement Amendments (CLIA)

Others

Application Insights

Vitamin D Testing

Bone Metabolism

Regional Insights

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and Middle East and Africa. According to the report, North America was the largest market for bone and mineral diagnostic testing. Some of the factors driving the North America bone and mineral diagnostic testing market include the expanding geriatric population, rising healthcare expenditure, extensive research and development (R&D) activities conducted by key players, etc.

Competitive Landscape

The report has also provided a comprehensive analysis of the competitive landscape in the global bone and mineral diagnostic testing market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Abbott Laboratories, bioMerieux SA, DiaSorin S.p.A., Epitope Diagnostics Inc., F. Hoffmann-La Roche AG, QuidelOrtho Corporation, Siemens Healthineers AG (Siemens AG), etc.

Key Questions Answered in This Report:

• How has the global bone and mineral diagnostic testing market performed so far and how will it perform in the coming years?
• What are the drivers, restraints, and opportunities in the global bone and mineral diagnostic testing market?
• What are the key regional markets?
• Which countries represent the most attractive bone and mineral diagnostic testing markets?
• What is the breakup of the market based on the product?
• What is the breakup of the market based on the test type?
• What is the breakup of the market based on the application?
• What is the competitive structure of the global bone and mineral diagnostic testing market?
• Who are the key players/companies in the global bone and mineral diagnostic testing market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Bone and Mineral Diagnostic Testing Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Product

• 6.1 Assays/Consumables
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Instruments
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast

7 Market Breakup by Test Type

• 7.1 Enzyme-Linked Immunosorbent Assay (ELISA)
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Clinical Laboratory Improvement Amendments (CLIA)
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Others
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast

8 Market Breakup by Application

• 8.1 Vitamin D Testing
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Bone Metabolism
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia-Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

• 10.1 Overview
• 10.2 Drivers
• 10.3 Restraints
• 10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 Abbott Laboratories
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
    • 14.3.1.3 Financials
    • 14.3.1.4 SWOT Analysis
  • 14.3.2 bioMerieux SA
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
    • 14.3.2.3 Financials
    • 14.3.2.4 SWOT Analysis
  • 14.3.3 DiaSorin S.p.A.
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
    • 14.3.3.3 Financials
    • 14.3.3.4 SWOT Analysis
  • 14.3.4 Epitope Diagnostics Inc.
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
  • 14.3.5 F. Hoffmann-La Roche AG
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
    • 14.3.5.3 Financials
  • 14.3.6 QuidelOrtho Corporation
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
  • 14.3.7 Siemens Healthineers AG (Siemens AG)
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Product Portfolio
    • 14.3.7.3 Financials
    • 14.3.7.4 SWOT Analysis

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.